The DTWD2 Knockout A-549 Polyclonal Cells provide a heterogeneous population of A-549 human lung adenocarcinoma cells with CRISPR/Cas9-mediated disruption of the DTWD2 gene. This polyclonal knockout model delivers a loss-of-function cell pool that minimizes clone-specific artifacts, making it well-suited for reproducible functional studies in a cancer-relevant context.
The A-549 cell line, isolated from the lung adenocarcinoma of a 58-year-old Caucasian male, displays an alveolar epithelial type II phenotype. As a widely used model, these adherent epithelial cells mirror key aspects of lung adenocarcinoma, including dysregulated proliferation, apoptosis resistance, and metastatic propensity, offering a clinically pertinent background for investigating oncogenic mechanisms.
The DTWD2 gene product is a predicted thiol-dependent deubiquitinase that hydrolyzes ubiquitin linkages on substrate proteins, regulating their stability, activity, or subcellular distribution. It operates within the ubiquitin-proteasome system, interacting with ubiquitin, E1 activating enzyme, E2 conjugating enzymes, E3 ubiquitin ligases, and proteasome subunits. DTWD2 is proposed to modulate NF-??B signaling by deubiquitinating pathway components, thereby influencing transcriptional responses. While direct substrates and upstream regulators remain uncharacterized, DTWD2 is connected to pathways such as ubiquitin-mediated proteolysis, protein processing in the endoplasmic reticulum, and NF-??B activation, with potential implications for stress-responsive signaling.
In the A-549 lung adenocarcinoma model, DTWD2 knockout is expected to perturb deubiquitinase activity, possibly impairing NF-??B-driven processes like cell survival, proliferation, and inflammation. This perturbation can be exploited to elucidate DTWD2??s contribution to tumorigenic phenotypes, even in the absence of confirmed disease associations. The model enables systematic dissection of DTWD2-dependent effects on cancer cell behavior, including proliferation, apoptosis, and migration.
Research applications include functional characterization of DTWD2 in lung cancer, target validation, and pharmacological screening of ubiquitin pathway inhibitors. Assays commonly used with these cells include Western blotting for knockout confirmation, cell viability (MTT) and colony formation for growth assessment, ubiquitination assays for enzymatic activity, NF-??B reporter assays for signaling readouts, apoptosis (Annexin V/PI) and migration/invasion assays for phenotypic analysis, and RNA-seq for transcriptome-wide impact. For additional technical details or custom inquiries, contact Ascent Research.
